Ovid Therapeutics Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
OVID$2.80-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(14,919) | $(3,174) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Change in fair value of royalty monetization liability | — | (29,028) |
| Unrealized loss (gain) on equity investments | 66 | (3,427) |
| Change in accrued interest and accretion of discount on marketable securities | (322) | (1,678) |
| Stock-based compensation expense | 2,503 | 3,708 |
| Depreciation and amortization expense | 240 | 284 |
| Noncash operating lease expense | 582 | 538 |
| Change in lease liability | (657) | (612) |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (878) | (151) |
| Accounts payable | 760 | 1,017 |
| Accrued expenses | (3,147) | 1,582 |
| Deferred revenue | 718 | — |
| Net cash used in operating activities | (15,054) | (30,941) |
| Cash flows from investing activities: | ||
| Purchase of marketable securities | (9,845) | (46,821) |
| Sales/maturities of marketable securities | 27,000 | 80,000 |
| Purchases of property and equipment | — | (53) |
| Software development and other costs | — | (116) |
| Net cash provided by investing activities | 17,155 | 33,010 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of options and purchases from employee stock purchase plan | 13 | 584 |
| Net cash provided by financing activities | 13 | 584 |
| Net increase in cash, cash equivalents and restricted cash | 2,114 | 2,653 |
| Cash, cash equivalents and restricted cash, at beginning of period | 28,232 | 28,972 |
| Cash, cash equivalents and restricted cash, at end of period | $30,346 | $31,625 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.